Bile Salt Export Pump (BSEP/ABCB11) Can Transport a Nonbile Acid Substrate, Pravastatin

Pravastatin is a well known 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor. Cumulative studies have shown that pravastatin is taken up into hepatocytes by the organic anion transporting polypeptide family transporters and excreted into the bile as an intact form by multidrug resistance-associated protein 2 (MRP2). It is generally accepted that the bile salt export pump (BSEP/ABCB11) mainly transports bile acids and plays an indispensable role in their biliary excretion. Interestingly, we found that BSEP could accept pravastatin as a substrate. Significant ATP-dependent uptake of pravastatin by human BSEP (hBSEP)- and rat BSEP (rBsep)-expressing membrane vesicles was observed, and the ratio of the uptake activity of pravastatin to that of taurocholic acid (TCA) by hBSEP was 3.3-fold higher than that by rBsep. The Km value of pravastatin for hBSEP was 124 μM. A mutual inhibition study between TCA and pravastatin revealed that they competitively interact with hBSEP. Several statins inhibited the hBSEP- and rBsep-mediated uptake of TCA; however, the specific uptake of other statins (cerivastatin, fluvastatin, and pitavastatin) by hBSEP and rBSEP was not detected. The inhibitory effects of hydrophilic statins (pravastatin and rosuvastatin) on the uptake of TCA by BSEP were relatively lower than those of lipophilic statins. These data suggest that BSEP may be partly involved in the biliary excretion of pravastatin in both rats and humans.

[1]  Y. Sugiyama,et al.  Two common PFIC2 mutations are associated with the impaired membrane trafficking of BSEP/ABCB11 , 2005, Hepatology.

[2]  E. Wang,et al.  Fluorescent Substrates of Sister-P-Glycoprotein (BSEP) Evaluated as Markers of Active Transport and Inhibition: Evidence for Contingent Unequal Binding Sites , 2003, Pharmaceutical Research.

[3]  Richard J. Thompson,et al.  The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. , 2002, Gastroenterology.

[4]  P. Meier,et al.  Functional expression of the canalicular bile salt export pump of human liver. , 2002, Gastroenterology.

[5]  Ronald T. Borchardt,et al.  Are MDCK Cells Transfected with the Human MDR1 Gene a Good Model of the Human Intestinal Mucosa? , 2002, Pharmaceutical Research.

[6]  R. Batey,et al.  Cholestasis associated with the use of pravastatin sodium , 2002, The Medical journal of Australia.

[7]  A. Guo,et al.  Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[8]  T. Abe,et al.  Transcellular Transport of Organic Anions Across a Double-transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-associated Protein 2 (MRP2/ABCC2)* , 2002, The Journal of Biological Chemistry.

[9]  T. Abe,et al.  Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. , 2001, The Journal of pharmacology and experimental therapeutics.

[10]  P. Meier,et al.  Characterization of the mouse bile salt export pump overexpressed in the baculovirus system , 2001, Hepatology.

[11]  Y. Sugiyama,et al.  A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[12]  W. Mück.  Clinical Pharmacokinetics of Cerivastatin , 2000, Clinical pharmacokinetics.

[13]  P. Meier,et al.  Transport function and hepatocellular localization of mrp6 in rat liver. , 2000, Molecular pharmacology.

[14]  T. Uchiumi,et al.  Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. , 1999, Molecular pharmacology.

[15]  J. Jiménez-Alonso,et al.  Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Grupo Lupus Virgen de las Nieves. , 1999, Archives of internal medicine.

[16]  I. Hirsch,et al.  Pulmonary edema associated with troglitazone therapy. , 1999, Archives of internal medicine.

[17]  P. Neuvonen,et al.  Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin , 1999, Clinical pharmacology and therapeutics.

[18]  H. Yawo,et al.  Pravastatin, an HMG-CoA Reductase Inhibitor, Is Transported by Rat Organic Anion Transporting Polypeptide, oatp2 , 1999, Pharmaceutical Research.

[19]  Hiroshi Suzuki,et al.  Characterization of the Transport Properties of Cloned Rat Multidrug Resistance-associated Protein 3 (MRP3)* , 1999, The Journal of Biological Chemistry.

[20]  H. Fujino,et al.  Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase (4) : Interspecies Variation in Laboratory Animals and Humans , 1999 .

[21]  P. Neuvonen,et al.  Grapefruit juice—simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG‐CoA reductase inhibitors , 1998, Clinical pharmacology and therapeutics.

[22]  Richard J. Thompson,et al.  A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis , 1998, Nature Genetics.

[23]  Y. Sugiyama,et al.  Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. , 1998, Pharmacological reviews.

[24]  C. Spurr,et al.  Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone , 1998, Annals of Internal Medicine.

[25]  P. Meier,et al.  The Sister of P-glycoprotein Represents the Canalicular Bile Salt Export Pump of Mammalian Liver* , 1998, The Journal of Biological Chemistry.

[26]  Y. Sugiyama,et al.  Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[27]  H. Lennernäs,et al.  Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors , 1997, Clinical pharmacokinetics.

[28]  M. Yamazaki,et al.  Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinemic rats. , 1996, Biopharmaceutics & drug disposition.

[29]  Y. Adachi,et al.  Pravastatin transport across the hepatocyte canalicular membrane requires both ATP and a transmembrane pH gradient , 1996, Journal of gastroenterology and hepatology.

[30]  P. Borst,et al.  Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  C. Goresky,et al.  Enalaprilat handling by the kidney: barrier-limited cell entry. , 1992, The American journal of physiology.

[32]  P. Opolon,et al.  Chronic administration of cyclosporin A induces a decrease in hepatic excretory function in man , 1992, Digestive Diseases and Sciences.

[33]  M. Campanini,et al.  Acute cholestatic hepatitis during simvastatin administration. , 1991, Recenti progressi in medicina.

[34]  Gudrun Wacker.  Similarities and Differences , 2005 .

[35]  Bruno Stieger,et al.  Enterohepatic bile salt transporters in normal physiology and liver disease. , 2004, Gastroenterology.

[36]  Ronald T. Borchardt,et al.  Are MDCK Cells Transfected with the Human MRP2 Gene a Good Model of the Human Intestinal Mucosa? , 2004, Pharmaceutical Research.

[37]  R. Kim,et al.  Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. , 2000, Molecular pharmacology.

[38]  Y. Sugiyama,et al.  Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2). , 2000, The Journal of pharmacology and experimental therapeutics.

[39]  Y. Sugiyama,et al.  Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. , 1993, The American journal of physiology.

[40]  T Nakagawa,et al.  A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.